In addition, we propose that gilteritinib may be a good combination drug with chemotherapies that increase plasma concentrations of FL in FLT3-mutated AML patients and/or an effective monotherapy for AML patients with FL upregulation after chemotherapy. Here, FLT3LG is linked to acute myeloid leukemia.